Oliveira, Nuno Arantes eGartmann, Martin Christoph2025-03-242025-03-242024-06-12http://hdl.handle.net/10362/181162TSD, a novel biotech venture, aims to revolutionise the wound healing market by utilising jellyfish, a new source of collagen. Its product, the CollaPatchTM, harnesses the benefits of jellyfish collagen across social, environmental, and ecological dimensions, offering a superior alternative to bovine- and porcine-based collagen products for wound healing. TSD strives to capture significant market share in the treatment of both acute and chronic wounds by presenting a comprehensive business model, covering the diverse user and customer needs, existing and potential competitors, the optimal path to commercialisation, the required steps in the development roadmap and valuable funding and exit opportunities.engEntrepreneurshipIntrapreneurshipVenture capitalInnovationPharmaceuticalBiotechnologyBiomedical innovationBusiness strategyIntellectual propertyCompetitive analysisFundingUlcersWound healingChronical woundsJellyfishmaster thesis203901886